Notably, tumor regression following therapeutic PD-1/PD-L1 blockade requires adequate antigenic T-cell response, tumor-infiltrating lymphocytes, and cytokine secretion such as IFN [132], which reflects the cooperation between innate and adaptive immunity. The gene discussed is CD274; the disease is neoplasm.